IL-6 blockade agents, such as tocilizumab and siltuximab, effectively control CRS symptoms but may inadequately prevent, or even exacerbate, neurotoxicity (immune effector cell-associated neurotoxicity syndrome, ICANS) 10, 11. The gene discussed is IL6; the disease is congenital rubella syndrome.